Abstract
Dengue is a serious mosquito-transmitted disease caused by the dengue virus (DENV). Rapid and reliable diagnosis of DENV infection is urgently needed in dengue-endemic regions. We describe here the performance evaluation of the CE-marked VIDAS® dengue immunoassays developed for the automated detection of DENV NS1 antigen, and anti-DENV IgM and IgG anti-bodies. A multicenter concordance study was conducted in 1296 patients from dengue-endemic regions in Asia, Latin America, and Africa. VIDAS® dengue results were compared to those of competitor enzyme-linked immunosorbent assays (ELISA). The VIDAS® dengue assays showed high precision (CV ≤ 10.7%) and limited cross-reactivity (≤ 15.4%) with other infections. VIDAS® DENGUE NS1 Ag showed high positive and negative percent agreement (92.8% PPA, 91.7% NPA) in acute patients within 0–5 days of symptom onset. VIDAS® Anti-DENGUE IgM and IgG showed a moderate to high concordance with ELISA (74.8% to 90.6%) in post-acute and recovery patients. PPA was further improved in combined VIDAS® NS1/IgM (96.4% in 0–5 days acute patients) and IgM/IgG (91.9% in post-acute patients) tests. Altogether, the VIDAS® dengue NS1, IgM and IgG assays performed well, either alone or in combination, and should be suitable for the accurate diagnosis of DENV infection in dengue-endemic regions.
Competing Interest Statement
L.B., L.D., F.S. and M.T. are employees of bioMerieux. M.L.N. and S.D. received compensation fees from bioMerieux for this study, in the framework of the agreement signed with their employer entity. This study was funded by bioMerieux. The funder was involved in the design and execution of the study, in data interpretation and in writing of the manuscript.
Funding Statement
This study was funded by bioMerieux.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the respective institutional review boards (Comite Ethique pour la Recherche en Sante [CERS], Ministere de la Sante, Ministere de Enseignement Superieur, Recherche Scientifique et Innovation, Burkina Faso, No. 2020-4-076, dated 8 April 2020; Ethics Committee for Research on Human Beings of the Faculty of Medicine of Sao Jose do Rio Preto, FAMERP, Brazil, No. 4.032.814, dated 18 May 2020 for the prospective collection and No. 02078812.8.0000.5415, dated 27 May 2019 for the retrospective collection). Written informed consent was obtained from all subjects involved in the study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
afversiani{at}gmail.com (A.F.V.); Thayza{at}gmail.com (T.M.I.L.S.); brunohgam{at}hotmail.com (B.H.G.A.M.); cassiafestofolete{at}gmail.com (C.F.E.); mauricio.nogueira{at}edu.famerp.br (M.L.N.)
aswkabore{at}yahoo.fr
ludovic.brossault{at}biomerieux.com (L.B.); loic.dromenq{at}biomerieux.com (L.D.); florence.senot{at}biomerieux.com (F.S.)
assanacisse{at}yahoo.fr (A.C.); diagbouga.serge{at}gmail.com (S.D.)
abelcyriac.sorgho{at}yahoo.fr
Additionnal data (Table S6): Concordance of the VIDAS dengue assays with the respective competitor ELISA, according to time intervals post symptom onset.
Data Availability
All data produced in the present work are contained in the manuscript.
